MedPath

Feasibility Study of a Systematic Approach for Deprescribing of Statins and PPI's.

Not Applicable
Completed
Conditions
Polypharmacy
Registration Number
NCT04204590
Lead Sponsor
Zuyderland Medisch Centrum
Brief Summary

Deprescribing, the process of safely reducing or discontinuing unnecessary or harmful medication, has the potential to decrease polypharmacy and improve health outcomes. In this study a structured implicit algorithm, focusing on both extrinsic medication factors (eg change in disease) and intrinsic patient factors (eg. pill burden) will be used.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
75
Inclusion Criteria
  • Participant uses a statin and/or a proton pump inhibitor.
  • Participant signs informed consent.
  • Participant is a nursing home resident.
Exclusion Criteria
  • Participant is there for short term nursing home admission (<3 months)
  • Participant is there for hospice admission.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Decrease in pill burden (the dose of statins and PPI's)3 and 6 months after intervention.

On T0 (intervention) and on T1 + T2 (3 and 6 months after intervention), we will measure the dose of PPI's and statins on the medication list of every participant. These are provided by the pharmacist.

Decrease in pill burden (the number of statins and PPI's)3 and 6 months after intervention.

On T0 (intervention) and on T1 + T2 (3 and 6 months after intervention), we will measure the number of PPI's and statins on the medication list of every participant. These are provided by the pharmacist.

Secondary Outcome Measures
NameTimeMethod
Feasibility to use this algorithm.3 and 6 months after intervention

Three and six months after intervention we will ask the participating doctors the next questions (per included participant):

* What did the algorithm advice you?

* Did you follow the advice?

* Why dit you follow/deny the advice?

All possible negative side effects of deprescribing (e.g. nausea, symptom recurrence)From intervention to six months after intervention

All possible negative effects of deprescribing as recognised by the doctor involved, e.g. symptom recurrence.

Trial Locations

Locations (1)

Lemborgh

🇳🇱

Sittard, Limburg, Netherlands

Lemborgh
🇳🇱Sittard, Limburg, Netherlands

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.